IP Library Granted Patent US 7,851,609
Granted Patent B2
US 7,851,609 · App. 11/781,199 · Granted Dec 14, 2010

Patent

Assignee: Emergent Product Development Gaithersburg Inc.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,851,609
App. No.
11/781,199
Granted
Dec 14, 2010
Kind
B2
Abstract

The invention discloses the Chlamydia PMPE and PMPI polypeptide, polypeptides derived therefrp, (PMP-derived polypeptides), nucleotide sequences encoding said polypeptides, antibodies that specifically bind the PMP polypeptides and PMP-derived polypeptides and T-cells specific for PMP polypeptides and PMP-derived polypeptides. Also disclosed are prophylactic and therapeutic compositions, including immunogenic compositions, e.g., vaccines, comprising PMP polypeptides or PMP-derived polypeptides or antibodies thereto. The invention additionally discloses methods of inducing in animals an immune response to Chlamydia cells, Chlamydia elementary bodies, and/or cells expressing Chlamydial proteins, e.g., cell infected with Chlamydia.

Claims (55)

1. An isolated polynucleotide comprising the nucleic acid sequence which encodes a polypeptide comprising the amino acid sequence selected from the group consisting of:

(a) amino acids 32-965 of SEQ ID NO: 2;

(b) SEQ ID NO: 2;

(c) amino acids 590-625 of SEQ ID NO: 2;

(d) amino acids 1-500 of SEQ ID NO: 2;

(e) amino acids 625-700 of SEQ ID NO: 2;

(f) the amino acid sequence encoded by the Chlamydia insert in E. coli M15 assigned as ATCC PTA No. 2462; and

(g) a combination of two or more amino acid sequences of (a)-(f).

2. The polynucleotide of claim 1 , wherein said polypeptide further comprises a heterologous polypeptide.

3. The polynucleotide of claim 2 , wherein said heterologous polypeptide is selected from the group consisting of a pre- and/or pro-sequence, an affinity purification sequence, and an immunogenic sequence.

4. The polynucleotide of claim 2 , wherein said heterologous polypeptide is selected from the group consisting of SEQ ID NO: 4; amino acids 13-40 of SEQ ID NO: 4; amino acids 70-110 of SEQ ID NO: 4; amino acids 150-225 of SEQ ID NO: 4; amino acids 250-290 of SEQ ID NO: 4; amino acids 370-455 of SEQ ID NO: 4; amino acids 400-455 of SEQ ID NO: 4; amino acids 470-520 of SEQ ID NO: 4; amino acids 615-670 of SEQ ID NO: 4; amino acids 710-775 of SEQ ID NO: 4; amino acids 765-825 of SEQ ID NO: 4; amino acids 830-860 of SEQ ID NO: 4; amino acids 1-500 of SEQ ID NO: 4; and the amino acid sequence encoded by the Chlamydia insert in E. coli TOP10 assigned as ATCC PTA No. 2461.

5. The polynucleotide of claim 1 , wherein said nucleic acid sequence is selected from the group consisting of:

(a) nucleotides 94-2895 of SEQ ID NO: 1;

(b) SEQ ID NO: 1;

(c) the Chlamydia insert in E. coli M15 assigned as ATCC PTA No. 2462; and

(d) a combination of (a), (b), or (c), or the complement thereof.

6. A vector comprising the polynucleotide of claim 1 .

7. A host cell comprising the vector of claim 6 .

8. A composition comprising the polynucleotide of claim 1 and a carrier.

9. The composition of claim 8 , further comprising an adjuvant.

10. An isolated polynucleotide comprising the nucleic acid sequence, which encodes a polypeptide comprising the amino acid sequence of SEQ ID NO: 4 or the amino acid sequence encoded by the Chlamydia insert in E. coli TOP10 assigned as ATCC PTA No. 2461.

11. The polynucleotide of claim 10 , wherein said polypeptide further comprises a heterologous polypeptide.

12. The polynucleotide of claim 11 , wherein said heterologous polypeptide is selected from the group consisting of a pre- and/or pro-sequence, an affinity purification sequence, and an immunogenic sequence.

13. The polynucleotide of claim 11 , wherein said heterologous polypeptide is selected from the group consisting of SEQ ID NO: 2; amino acids 32-965 of SEQ ID NO: 2; amino acids 15-56 of SEQ ID NO: 2; amino acids 15-121 of SEQ ID NO: 2; amino acids 45-125 of SEQ ID NO: 2; amino acids 125-190 of SEQ ID NO: 2; amino acids 195-261 of SEQ ID NO: 2; amino acids 275-366 of SEQ ID NO: 2; amino acids 375-440 of SEQ ID NO: 2; amino acids 440-490 of SEQ ID NO: 2; amino acids 525-590 of SEQ ID NO: 2; amino acids 590-625 of SEQ ID NO: 2; amino acids 615-650 of SEQ ID NO: 2; amino acids 625-700 of SEQ ID NO: 2; amino acids 725-800 of SEQ ID NO: 2; amino acids 755-775 of SEQ ID NO: 2; amino acids 785-845 of SEQ ID NO: 2; amino acids 815-865 of SEQ ID NO: 2; amino acids 1-31 of SEQ ID NO: 2; amino acids 1-500 of SEQ ID NO: 2; and the amino acid sequence encoded by the Chlamydia insert in E. coli M15 assigned as ATCC PTA No. 2462.

14. The polynucleotide of claim 10 , wherein said nucleic acid sequence is SEQ ID NO:3 or the Chlamydia insert in E. coli TOP10 assigned as ATCC PTA No. 2461.

15. A vector comprising the polynucleotide of claim 10 .

16. A host cell comprising the vector of claim 15 .

17. A composition comprising the polynucleotide of claim 10 and a carrier.

18. The composition of claim 17 , further comprising an adjuvant.

19. An isolated polynucleotide encoding a polypeptide, which consists of the amino acid sequence selected from the group consisting of: amino acids 32-965 of SEQ ID NO: 2; SEQ ID NO: 2; the amino acid sequence encoded by the Chlamydia insert in E. coli M15 assigned as ATCC PTA No. 2462; amino acids 15-56 of SEQ ID NO: 2; amino acids 15-121 of SEQ ID NO: 2; amino acids 45-125 of SEQ ID NO: 2; amino acids 125-190 of SEQ ID NO: 2; amino acids 195-261 of SEQ ID NO: 2; amino acids 275-366 of SEQ ID NO: 2; amino acids 375-440 of SEQ ID NO: 2; amino acids 440-490 of SEQ ID NO: 2; amino acids 525-590 of SEQ ID NO: 2; amino acids 590-625 of SEQ ID NO: 2; amino acids 615-650 of SEQ ID NO: 2; amino acids 625-700 of SEQ ID NO: 2; amino acids 725-800 of SEQ ID NO: 2; amino acids 755-775 of SEQ ID NO: 2; amino acids 785-845 of SEQ ID NO: 2; amino acids 815-865 of SEQ ID NO: 2; amino acids 1-31 of SEQ ID NO: 2; and amino acids 1-500 of SEQ ID NO: 2.

20. A vector comprising the polynucleotide of claim 19 .

21. A host cell comprising the vector of claim 20 .

22. A composition comprising the polynucleotide of claim 19 and a cattier.

23. The composition of claim 22 , further comprising an adjuvant.

24. The composition of claim 22 , further comprising a heterologous polynucleotide.

25. The composition of claim 24 , wherein said heterologous polynucleotide encodes the amino acid sequence, which is selected from the group consisting of SEQ ID NO: 4; amino acids 13-40 of SEQ ID NO: 4; amino acids 70-110 of SEQ ID NO: 4; amino acids 150-225 of SEQ ID NO: 4; amino acids 250-290 of SEQ ID NO: 4; amino acids 370-455 of SEQ ID NO: 4; amino acids 400-455 of SEQ ID NO: 4; amino acids 470-520 of SEQ ID NO: 4; amino acids 615-670 of SEQ ID NO: 4; amino acids 710-775 of SEQ ID NO: 4; amino acids 765-825 of SEQ ID NO: 4; amino acids 830-860 of SEQ ID NO: 4; amino acids 1-500 of SEQ ID NO: 4; and the amino acid sequence encoded by the Chlamydia insert in E. coli TOP10 assigned as ATCC PTA No. 2461.

26. An isolated polynucleotide encoding a polypeptide, which consists of the amino acid sequence selected from the group consisting of: SEQ ID NO: 4; amino acids 13-40 of SEQ ID NO: 4; amino acids 70-110 of SEQ ID NO: 4; amino acids 150-225 of SEQ ID NO: 4; amino acids 250-290 of SEQ ID NO: 4; amino acids 370-455 of SEQ ID NO: 4; amino acids 400-455 of SEQ ID NO: 4; amino acids 470-520 of SEQ ID NO: 4; amino acids 615-670 of SEQ ID NO: 4; amino acids 710-775 of SEQ ID NO: 4; amino acids 765-825 of SEQ ID NO: 4; amino acids 830-860 of SEQ ID NO: 4; and amino acids 1-500 of SEQ ID NO: 4.

27. A vector comprising the polynucleotide of claim 26 .

28. A host cell comprising the vector of claim 27 .

29. A composition comprising the polynucleotide of claim 26 and a carrier.

30. The composition of claim 29 , further comprising an adjuvant.

31. The composition of claim 29 , further comprising a heterologous polynucleotide.

32. The composition of claim 31 , wherein said heterologous polynucleotide encodes the amino acid sequence, which is selected from the group consisting of SEQ ID NO: 2; amino acids 15-56 of SEQ ID NO: 2; amino acids 15-121 of SEQ ID NO: 2; amino acids 45-125 of SEQ ID NO: 2; amino acids 125-190 of SEQ ID NO: 2; amino acids 195-261 of SEQ ID NO: 2; amino acids 275-366 of SEQ ID NO: 2; amino acids 375-440 of SEQ ID NO: 2; amino acids 440-490 of SEQ ID NO: 2; amino acids 525-590 of SEQ ID NO: 2; amino acids 590-625 of SEQ ID NO: 2; amino acids 615-650 of SEQ ID NO: 2; amino acids 625-700 of SEQ ID NO: 2; amino acids 725-800 of SEQ ID NO: 2; amino acids 755-775 of SEQ ID NO: 2; amino acids 785-845 of SEQ ID NO: 2; amino acids 815-865 of SEQ ID NO: 2; amino acids 1-31 of SEQ ID NO: 2; amino acids 1-500 of SEQ ID NO: 2; and the amino acid sequence encoded by the Chlamydia insert in E. coli M15 assigned as ATCC PTA No. 2462.

33. An isolated polynucleotide comprising a nucleotide sequence, which encodes a polypeptide comprising the amino acid sequence selected from the group consisting of: amino acids 32-965 of SEQ ID NO: 2; SEQ ID NO: 2; the amino acid sequence encoded by the Chlamydia insert in E. coli M15 assigned as ATCC PTA No. 2462; amino acids 15-56 of SEQ ID NO: 2; amino acids 15-121 of SEQ ID NO: 2; amino acids 45-125 of SEQ ID NO: 2; amino acids 125-190 of SEQ ID NO: 2; amino acids 195-261 of SEQ ID NO: 2; amino acids 275-366 of SEQ ID NO: 2; amino acids 375-440 of SEQ ID NO: 2; amino acids 440-490 of SEQ ID NO: 2; amino acids 525-590 of SEQ ID NO: 2; amino acids 590-625 of SEQ ID NO: 2; amino acids 615-650 of SEQ ID NO: 2; amino acids 625-700 of SEQ ID NO: 2; amino acids 725-800 of SEQ ID NO: 2; amino acids 755-775 of SEQ ID NO: 2; amino acids 785-845 of SEQ ID NO: 2; amino acids 815-865 of SEQ ID NO: 2; amino acids 1-31 of SEQ ID NO: 2; and amino acids 1-500 of SEQ ID NO: 2, wherein said polypeptide further comprises a heterologous polypeptide.

34. The polynucleotide of claim 33 , wherein said heterologous polypeptide is selected from the group consisting of a pre- and/or pro-sequence, an affinity purification sequence, and an immunogenic sequence.

35. The polynucleotide of claim 33 , wherein said heterologous polypeptide comprises the amino acid sequence selected from the group consisting of SEQ ID NO: 4; amino acids 13-40 of SEQ ID NO: 4; amino acids 70-110 of SEQ ID NO: 4; amino acids 150-225 of SEQ ID NO: 4; amino acids 250-290 of SEQ ID NO: 4; amino acids 370-455 of SEQ ID NO: 4; amino acids 400-455 of SEQ ID NO: 4; amino acids 470-520 of SEQ ID NO: 4; amino acids 615-670 of SEQ ID NO: 4; amino acids 710-775 of SEQ ID NO: 4; amino acids 765-825 of SEQ ID NO: 4; amino acids 830-860 of SEQ ID NO: 4; amino acids 1-500 of SEQ ID NO: 4; and the amino acid sequence encoded by the Chlamydia insert in E. coli TOP10 assigned as ATCC PTA No. 2461.

36. A vector comprising the polynucleotide of claim 33 .

37. A host cell comprising the vector of claim 36 .

38. A composition comprising the polynucleotide of claim 33 and a carrier.

39. An isolated polynucleotide comprising a nucleotide sequence, which encodes a polypeptide comprising the amino acid sequence selected from the group consisting of: amino acids 13-40 of SEQ ID NO: 4; amino acids 70-110 of SEQ ID NO: 4; amino acids 150-225 of SEQ ID NO: 4; amino acids 250-290 of SEQ ID NO: 4; amino acids 370-455 of SEQ ID NO: 4; amino acids 400-455 of SEQ ID NO: 4; amino acids 470-520 of SEQ ID NO: 4; amino acids 615-670 of SEQ ID NO: 4; amino acids 710-775 of SEQ ID NO: 4; amino acids 765-825 of SEQ ID NO: 4; amino acids 830-860 of SEQ ID NO: 4; and amino acids 1-500 of SEQ ID NO: 4, wherein said polypeptide further comprises a heterologous polypeptide.

40. The polynucleotide of claim 39 , wherein said heterologous polypeptide is selected from the group consisting of a pre- and/or pro-sequence, an affinity purification sequence, and an immunogenic sequence.

41. The polynucleotide of claim 39 , wherein said heterologous polypeptide comprises the amino acid sequence selected from the group consisting of SEQ ID NO: 2; amino acids 15-56 of SEQ ID NO: 2; amino acids 15-121 of SEQ ID NO: 2; amino acids 45-125 of SEQ ID NO: 2; amino acids 125-190 of SEQ ID NO: 2; amino acids 195-261 of SEQ ID NO: 2; amino acids 275-366 of SEQ ID NO: 2; amino acids 375-440 of SEQ ID NO: 2; amino acids 440-490 of SEQ ID NO: 2; amino acids 525-590 of SEQ ID NO: 2; amino acids 590-625 of SEQ ID NO: 2; amino acids 615-650 of SEQ ID NO: 2; amino acids 625-700 of SEQ ID NO: 2; amino acids 725-800 of SEQ ID NO: 2; amino acids 755-775 of SEQ ID NO: 2; amino acids 785-845 of SEQ ID NO: 2; amino acids 815-865 of SEQ ID NO: 2; amino acids 1-31 of SEQ ID NO: 2; amino acids 1-500 of SEQ ID NO: 2; and the amino acid sequence encoded by the Chlamydia insert in E. coli M15 assigned as ATCC PTA No. 2462.

42. A vector comprising the polynucleotide of claim 39 .

43. A host cell comprising the vector of claim 42 .

44. A composition comprising the polynucleotide of claim 39 and a carrier.

Assignments (5)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 12, 2010
From: JACKSON, W. JAMES
To: ANTEX BIOLOGICS INC.
Reel/Frame 024370/0827 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 12, 2010
From: ANTEX BIOLOGICS INC.
To: BIOPORT R&D, INC.
Reel/Frame 024370/0857 →
CHANGE OF NAME Recorded May 12, 2010
From: BIOPORT R&D, INC.
To: ANTEX BIOLOGICS INC.
Reel/Frame 024370/0934 →
CHANGE OF NAME Recorded May 12, 2010
From: ANTEX BIOLOGICS INC.
To: EMERGENT IMMUNOSOLUTIONS INC.
Reel/Frame 024371/0101 →
CHANGE OF NAME Recorded May 12, 2010
From: EMERGENT IMMUNOSOLUTIONS INC.
To: EMERGENT PRODUCT DEVELOPMENT GAITHERSBURG INC.
Reel/Frame 024371/0141 →
Continuity (3)
Division 1039824800
Continuation In Part 0967775200 · Oct 2, 2000
Related Publication 20070292437A1 · Dec 20, 2007